We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Sekisui Diagnostics

Download Mobile App





Virusight Diagnostic’s AI Solution for COVID-19 1-Second Test Demonstrates Excellent Correlation to PCR

By LabMedica International staff writers
Posted on 16 Nov 2020
A solution for instant COVID-19 screening from Virusight Diagnostic Ltd. More...
(Ramat Gan, Israel) has demonstrated a high correlation to PCR in pre-clinical testing.

The pre-clinical testing included hundreds of real swab samples of COVID-19 infected and non-infected patients, taken before PCR. In this initial test, Virusight’s solution demonstrated a very high correlation to PCR while testing 130 non-labeled samples out of a total 330 samples.
The instant screening solution from Virusight, a JV of Newsight Imaging Ltd. (Ness Ziona, Israel) and the ARC Innovation Center of Sheba Medical Center (Tel HaShomer, Israel), is based on licensing of Newsight’s SpectraLIT - a game changing spectral device, together with a special AI software. The device is capable of checking a swab’s UTM liquid, or mouthwash, in only one second, using an absorbance spectrographic method.

Virusight currently has 26 active pilots with leading hospitals around the world, aiming to achieve local validation of its technology, parallel to its efforts to obtain regulation approvals. The pilots are conducted in collaboration with local partners. Alongside European countries and other areas worldwide, Virusight has already secured its distribution in Asia Pacific, signing an MOU with AI Innobio to sell 50 million tests to APAC countries to be used within one year.

“I am so excited to bring the SpectraLIT technology to the APAC region,” said Dr. George So, Chairman and acting CEO of AI InnoBio. “AI InnoBio has signed MOU with partners in eight countries in this region to introduce the “FAIR” AIIB SpectraLIT COVID-19 quick test solution for the current pandemic. We will soon start pilot studies in five countries, including India, Philippines, South Korea, Singapore, etc. AIIB SpectraLIT is “FAIR” because the technology is Fast, Affordable, Innovative and Reliable. This quick test can be used as a screening device between countries to safeguard travel bubbles and kick start economy recovery in the APAC region.”

“Virusight is in a great momentum forward,” said Eli Assoolin, Board Chairman and Acting CEO of Virusight Diagnostic. Virusight Diagnostic’s solution, powered by Newsight Imaging’s technology and Sheba Medical Center’s excellence, is about to enable affordable mass screening checks for everyone, and help the world resume normal life. We are very excited to be a part of this important goal.”

Related Links:
Virusight Diagnostic Ltd.
Newsight Imaging Ltd.
Sheba Medical Center



Gold Member
Universal Transport Solution
Puritan®UniTranz-RT
βeta-Hydroxybutyrate Reagent
β-Hydroxybutyrate LiquiColor®
Fully Automated Urinalysis System
DxU 1800 Fully Automated Urinalysis System
MR-proADM Test
B•R•A•H•M•S MR-proADM KRYPTOR test
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: Blood proteins measured years before diagnosis may signal future prostate cancer risk, including aggressive disease.(Image Credit: iStock)

Blood Proteins Reveal Signals Linked to Prostate Cancer Risk Years Before Diagnosis

Prostate cancer is the most commonly diagnosed cancer in men worldwide. While many tumors grow slowly, aggressive forms can be life-threatening, underscoring the need for earlier risk identification.... Read more

Immunology

view channel
Image Credit: iStock

Antibody Profiling Predicts Inflammatory Bowel Disease Years Before Diagnosis

Inflammatory bowel disease (IBD), which includes Crohn’s disease and ulcerative colitis, involves abnormal immune responses that cause persistent inflammation and damage in the digestive system.... Read more

Pathology

view channel
Image Credit: iStock

AI Tissue Analysis May Help Identify Missed Precancerous Colon Polyps

Colorectal cancer is diagnosed in an estimated 1.9 million people worldwide each year, often without symptoms in its early stages. Timely detection of precancerous lesions is therefore important, yet some... Read more

Technology

view channel
Image: Signals LabGistics uses AI to turn natural-language instructions and SOPs into coordinated scientific workflows, helping connect teams, systems, and processes. (Photo courtesy of Revvity)

New AI-Powered System Aims to Streamline Laboratory and Manufacturing Workflows

Scientific laboratories supporting drug development, biotechnology, and materials research increasingly rely on coordinated digital workflows to move data, samples, and activities across teams.... Read more

Industry

view channel
Image: Beginning in 2027, Quest will provide access to the Onclarity Self-Collection Kit through clinician, health plan, and consumer-initiated testing channels, along with its patient service center network.

Collaboration to Expand Cervical Cancer Screening Access With At-Home HPV Collection

Cervical cancer is largely preventable with regular screening and early detection of human papillomavirus (HPV), the leading cause of the disease. Screening gaps persist, in part because traditional sample... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.